Oral yohimbine as a new probe drug to predict CYP2D6 activity: results of a fixed-sequence phase I trial
Yohimbine pharmacokinetics were determined after oral administration of a single oral dose of yohimbine 5 mg and a microdose of yohimbine 50 µg in relation to different cytochrome P450 (CYP) 2D6 genotypes. The CYP2D6 inhibitor paroxetine was used to investigate the influence on yohimbine pharmacokin...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 February 2020
|
| In: |
Clinical pharmacokinetics
Year: 2020, Jahrgang: 59, Heft: 7, Pages: 927-939 |
| ISSN: | 1179-1926 |
| DOI: | 10.1007/s40262-020-00862-6 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s40262-020-00862-6
|
| Verfasserangaben: | Manuela Vay, Marleen Julia Meyer, Antje Blank, Gisela Skopp, Peter Rose, Mladen Vassilev Tzvetkov, Gerd Mikus |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1766552552 | ||
| 003 | DE-627 | ||
| 005 | 20240414193257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210812s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40262-020-00862-6 |2 doi | |
| 035 | |a (DE-627)1766552552 | ||
| 035 | |a (DE-599)KXP1766552552 | ||
| 035 | |a (OCoLC)1295680753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Vay, Manuela |d 1990- |e VerfasserIn |0 (DE-588)1181123127 |0 (DE-627)1662506872 |4 aut | |
| 245 | 1 | 0 | |a Oral yohimbine as a new probe drug to predict CYP2D6 activity |b results of a fixed-sequence phase I trial |c Manuela Vay, Marleen Julia Meyer, Antje Blank, Gisela Skopp, Peter Rose, Mladen Vassilev Tzvetkov, Gerd Mikus |
| 264 | 1 | |c 15 February 2020 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.08.2021 | ||
| 520 | |a Yohimbine pharmacokinetics were determined after oral administration of a single oral dose of yohimbine 5 mg and a microdose of yohimbine 50 µg in relation to different cytochrome P450 (CYP) 2D6 genotypes. The CYP2D6 inhibitor paroxetine was used to investigate the influence on yohimbine pharmacokinetics. Microdosed midazolam was applied to evaluate a possible impact of yohimbine on CYP3A activity and the possibility of combining microdosed yohimbine and midazolam to simultaneously determine CYP2D6 and CYP3A activity. | ||
| 700 | 1 | |a Meyer, Marleen J. |e VerfasserIn |0 (DE-588)1226963579 |0 (DE-627)1748075969 |4 aut | |
| 700 | 1 | |a Blank, Antje |e VerfasserIn |0 (DE-588)1061215962 |0 (DE-627)805162364 |0 (DE-576)174275722 |4 aut | |
| 700 | 1 | |a Skopp, Gisela |d 1951- |e VerfasserIn |0 (DE-588)1060738538 |0 (DE-627)800969413 |0 (DE-576)164452346 |4 aut | |
| 700 | 1 | |a Rose, Peter |d 1989- |e VerfasserIn |0 (DE-588)1221682016 |0 (DE-627)1739014219 |4 aut | |
| 700 | 1 | |a Tzvetkov, Mladen Vassilev |d 1974- |e VerfasserIn |0 (DE-588)132827670 |0 (DE-627)690909837 |0 (DE-576)267140959 |4 aut | |
| 700 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacokinetics |d Berlin [u.a.] : Springer, 1976 |g 59(2020), 7, Seite 927-939 |h Online-Ressource |w (DE-627)327644974 |w (DE-600)2043781-X |w (DE-576)10337339X |x 1179-1926 |7 nnas |a Oral yohimbine as a new probe drug to predict CYP2D6 activity results of a fixed-sequence phase I trial |
| 773 | 1 | 8 | |g volume:59 |g year:2020 |g number:7 |g pages:927-939 |g extent:13 |a Oral yohimbine as a new probe drug to predict CYP2D6 activity results of a fixed-sequence phase I trial |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s40262-020-00862-6 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210812 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |d 50000 |e 910000PM110903137 |e 910100PM110903137 |e 50000PM110903137 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 7 |y j | ||
| 998 | |g 1221682016 |a Rose, Peter |m 1221682016:Rose, Peter |d 910000 |d 910200 |e 910000PR1221682016 |e 910200PR1221682016 |k 0/910000/ |k 1/910000/910200/ |p 5 | ||
| 998 | |g 1060738538 |a Skopp, Gisela |m 1060738538:Skopp, Gisela |d 910000 |d 912100 |d 50000 |e 910000PS1060738538 |e 912100PS1060738538 |e 50000PS1060738538 |k 0/910000/ |k 1/910000/912100/ |k 0/50000/ |p 4 | ||
| 998 | |g 1061215962 |a Blank, Antje |m 1061215962:Blank, Antje |d 910000 |d 910100 |e 910000PB1061215962 |e 910100PB1061215962 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 1181123127 |a Vay, Manuela |m 1181123127:Vay, Manuela |d 50000 |e 50000PV1181123127 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1766552552 |e 396630838X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Oral yohimbine as a new probe drug to predict CYP2D6 activity","subtitle":"results of a fixed-sequence phase I trial","title":"Oral yohimbine as a new probe drug to predict CYP2D6 activity"}],"person":[{"role":"aut","given":"Manuela","family":"Vay","display":"Vay, Manuela","roleDisplay":"VerfasserIn"},{"family":"Meyer","display":"Meyer, Marleen J.","roleDisplay":"VerfasserIn","role":"aut","given":"Marleen J."},{"roleDisplay":"VerfasserIn","display":"Blank, Antje","family":"Blank","given":"Antje","role":"aut"},{"role":"aut","given":"Gisela","roleDisplay":"VerfasserIn","family":"Skopp","display":"Skopp, Gisela"},{"role":"aut","given":"Peter","family":"Rose","display":"Rose, Peter","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Tzvetkov, Mladen Vassilev","family":"Tzvetkov","role":"aut","given":"Mladen Vassilev"},{"roleDisplay":"VerfasserIn","display":"Mikus, Gerd","family":"Mikus","given":"Gerd","role":"aut"}],"note":["Gesehen am 12.08.2021"],"recId":"1766552552","physDesc":[{"extent":"13 S."}],"language":["eng"],"id":{"doi":["10.1007/s40262-020-00862-6"],"eki":["1766552552"]},"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"Clinical pharmacokinetics","title":"Clinical pharmacokinetics"}],"part":{"text":"59(2020), 7, Seite 927-939","issue":"7","extent":"13","year":"2020","pages":"927-939","volume":"59"},"note":["Gesehen am 06.03.13","Ungezählte Beil.: Suppl"],"pubHistory":["1.1976 -"],"disp":"Oral yohimbine as a new probe drug to predict CYP2D6 activity results of a fixed-sequence phase I trialClinical pharmacokinetics","origin":[{"publisher":"Springer ; Adis Intern.","dateIssuedDisp":"1976-","publisherPlace":"Berlin [u.a.] ; Auckland","dateIssuedKey":"1976"}],"recId":"327644974","physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1179-1926"],"zdb":["2043781-X"],"eki":["327644974"]},"language":["eng"]}],"name":{"displayForm":["Manuela Vay, Marleen Julia Meyer, Antje Blank, Gisela Skopp, Peter Rose, Mladen Vassilev Tzvetkov, Gerd Mikus"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"15 February 2020"}]} | ||
| SRT | |a VAYMANUELAORALYOHIMB1520 | ||